Avalo Therapeutics, Inc. $AVTX Shares Bought by Renaissance Technologies LLC

Renaissance Technologies LLC lifted its holdings in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) by 556.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 120,114 shares of the company’s stock after acquiring an additional 101,814 shares during the quarter. Renaissance Technologies LLC’s holdings in Avalo Therapeutics were worth $1,793,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the business. Boothbay Fund Management LLC purchased a new position in Avalo Therapeutics in the second quarter valued at about $56,000. Dimensional Fund Advisors LP acquired a new stake in Avalo Therapeutics during the 3rd quarter valued at approximately $143,000. AlphaCentric Advisors LLC purchased a new stake in Avalo Therapeutics during the 1st quarter worth approximately $174,000. Jump Financial LLC purchased a new stake in Avalo Therapeutics during the 4th quarter worth approximately $238,000. Finally, Persistent Asset Partners Ltd acquired a new position in shares of Avalo Therapeutics in the 4th quarter valued at approximately $274,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

Insider Buying and Selling

In other Avalo Therapeutics news, insider Mittie Doyle sold 1,450 shares of Avalo Therapeutics stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total value of $26,100.00. Following the completion of the transaction, the insider owned 51,776 shares of the company’s stock, valued at $931,968. The trade was a 2.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.46% of the stock is currently owned by corporate insiders.

Trending Headlines about Avalo Therapeutics

Here are the key news stories impacting Avalo Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $30 price target, implying substantial upside from recent trading levels. Bank of America Securities also reaffirmed its Buy rating, providing continued analyst support. Bank of America Securities Reaffirms Buy Rating
• Neutral Sentiment: Reported short interest was listed at zero shares, unchanged from the prior period, with a zero-day days-to-cover ratio. This suggests no meaningful short-selling signal, but the reported figures appear unreliable because the entry describes the change as “NaN.”
• Negative Sentiment: HC Wainwright reduced its FY2026 EPS forecast to a loss of $2.76 from $2.02 and its FY2027 forecast to a loss of $2.41 from $1.78. Quarterly estimates for Q3 and Q4 2026 and each quarter of 2027 were also lowered, indicating expectations for deeper or more persistent losses. HC Wainwright Cuts Avalo Therapeutics Price Target
• Negative Sentiment: The earnings outlook remains challenging: Avalo recently reported a quarterly loss that missed expectations, while analysts continue to forecast significant losses. A separate report highlighted widening losses, even as improving EPS trends may indicate a potential strategic transition. Avalo Therapeutics Widening Losses and EPS Outlook

Avalo Therapeutics Stock Down 1.5%

NASDAQ:AVTX opened at $19.47 on Wednesday. The business’s 50 day moving average is $17.45 and its two-hundred day moving average is $16.36. Avalo Therapeutics, Inc. has a 52 week low of $8.41 and a 52 week high of $24.27. The company has a market cap of $1.04 billion, a PE ratio of -4.46 and a beta of 0.80.

Avalo Therapeutics (NASDAQ:AVTX) last issued its earnings results on Thursday, August 6th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.25). As a group, sell-side analysts expect that Avalo Therapeutics, Inc. will post -2.59 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Weiss Ratings cut Avalo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. Leerink Partners assumed coverage on shares of Avalo Therapeutics in a research note on Monday, July 6th. They issued an “outperform” rating and a $38.00 price target for the company. Bank of America initiated coverage on shares of Avalo Therapeutics in a report on Friday, June 12th. They issued a “buy” rating and a $35.00 price target on the stock. HC Wainwright reduced their price objective on shares of Avalo Therapeutics from $35.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Finally, Citigroup reissued an “outperform” rating on shares of Avalo Therapeutics in a report on Wednesday, May 6th. Thirteen equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.10.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.